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Glioneuronal tumors are an increasingly recognized cause of partial seizures that occur primarily in children and young adults.
Focal epilepsy associated with glioneuronal tumors is often resistant to pharmacological treatment. The cellular mechanisms
underlying the epileptogenicity of glioneuronal tumors remain largely unknown. The involved mechanisms are certain to be
multifactorial and depend on speciﬁc tumor histology, integrity of the blood-brain barrier, characteristics of the peritumoral
environment,circuitabnormalities,orcellularandmoleculardefects.Glioneuronaltumorspresentingwithepilepsywereobserved
to have relatively benign biological behavior. The completeness of the tumor resection is of paramount importance in avoiding
tumor progression and malignant transformation, which are rare in cases of epileptogenic glioneuronal tumors. An evolving
understanding of the various mechanisms of tumor-related epileptogenicity may also lead to a more deﬁned surgical objective and
eﬀective therapeutic strategies, including antiepileptogenic treatments, to prevent epilepsy in at-risk patients.
1.Introduction
Glioneuronal tumors are an increasingly recognized cause of
partial seizures that occur primarily in children and young
adults [1, 2].
Thesearetumorswithanadmixtureofglialandneuronal
components. Both cell types are thought to be part of the
same neoplastic process. Entrapment of preexisting neurons
by an inﬁltrating glioma therefore has to be distinguished
from glioneuronal tumors. More well-established examples
of glioneuronal tumors include dysembryoplastic neuroep-
ithelial tumors (DNTs) ganglioglioma and desmoplastic
infantile ganglioglioma. More recently recognized entities
partlyincludedinthelatestversionoftheWHOclassiﬁcation
include the rosette-forming tumor of the fourth ventricle
the papillary glioneuronal tumor and rosetted glioneuronal
tumor/glioneuronal tumor with neuropil-like islands. The
glial component in these tumors varies but often resembles
either a pilocytic astrocytoma or an inﬁltrating glioma with
astrocytic or oligodendroglial features [3].
Gangliogliomas and DNTs arise most commonly in the
temporal lobe and appear to be associated with an increased
incidence of cortical dysplasia or neuronal migration abnor-
malities [1, 4, 5].
Focal epilepsy that is often resistant to pharmacological
treatment is a common presenting symptom of glioneuronal
tumors [1, 2]. Even though the biological behavior of these
tumors is usually benign, especially when patients present
only with epilepsy, cases of tumor progression or malignant
transformation have been reported [1, 6, 7].
While a subset of epilepsy patients with glioneuronal
tumors may be candidates for epilepsy surgery, a better
understanding of underlying mechanisms of epileptogenesis
in this group of developmental brain disorders could lead to
more eﬀective therapeutic strategies, including antiepilepto-
genic treatments to prevent epilepsy in at-risk patients.
2. Epileptogenesis
The cellular mechanism(s) underlying the epileptogenicity
of glioneuronal tumors remain largely unknown. The high
success rate of “lesionectomy” during epilepsy surgery, with
many studies reporting over a 60–75% seizure-free rate,
also supports the idea that the lesions directly produce
seizures [8–10]. However, this still leaves a substantial
minority of patients that continue to have seizures following
lesionectomy, suggesting that the epileptogenic zone was not2 ISRN Neurology
contained within the lesion in those cases. Furthermore,
the success of lesionectomy in eliminating seizures may
have other interpretations: the margins of resection typically
contain some “normal” perilesional tissue, which may
actually be the primary source of the seizures. Alternatively,
perilesional cortex, immediately adjacent to or even distant
from the lesion, may generate the seizures, but may be
somehow dependent on the lesion for epileptogenesis.
Another controversial issue is whether epileptogenesis in
malformations of cortical development is primarily due to
circuit abnormalities or cellular and molecular defects [11].
A growing intracranial lesion can both structurally and
functionally alter the surrounding brain tissue with edema,
vascular insuﬃciency, inﬂammation, and release of metabol-
ically active molecules, hence also promoting seizure activity.
The involved mechanisms are certain to be multifactorial
and depend on speciﬁc tumor histology, integrity of the
blood-brain barrier, and characteristics of the peritumoral
environment [12].
Seizures clearly consist of synchronous electrical activ-
ity reverberating through complex neuronal networks and
thus ultimately must always include abnormalities on the
circuitlevel.Ultimately,bothnetworkandcellular/molecular
abnormalities will stimulate epileptogenesis by upsetting
the normal physiological balance between excitation and
inhibition in the brain [11].
An important role in hyperexcitability has been attrib-
uted to the neuronal component of these lesions, consist-
ing of highly diﬀerentiated cells containing, for example,
neuropeptides, neurotrophins, gap junctions, and receptors
for diﬀerent neurotransmitters [2, 8, 13–15]. Neuron-glia
interactions may also play a critical role in the genera-
tion of seizures. Accordingly, several studies demonstrate
alterations of functional properties of glial cells, involving
plasma membrane channels and receptors that might be
involved in epileptogenesis [16]. A recent hypothesis is
that the presence of activated astrocytes and microglia in
focal cortical dysplasia and glioneuronal tumors may be
related to the epileptogenicity of these lesions through the
production of inﬂammatory cytokines [17, 18]. Particular
attention has been focused on the role of the interleukin-
1β-( I L - 1 β-) activated pathways in ictogenesis. Intracerebral
application of IL-1β in rodents prolongs seizure activity
[19]. Accordingly, intracerebral application of the natu-
rally occurring antagonist of the IL-1 receptor (IL-1Ra)
mediates powerful anticonvulsant eﬀects [18]. Inhibition
of the production of the biologically active form of IL-
1β using blockers of interleukin-converting enzyme, also
named caspase-1, signiﬁcantly reduces seizures in rodents
[20]. These observations strongly support a proconvulsant
role of IL-1β produced in the brain in pathological con-
ditions, such as during seizures or as a consequence of
underlying inﬂammatory processes [19, 21]. It has been
shown also that the density of activated microglia (one
major source of cytokines in the brain) in focal cortical
dysplasia and glioneuronal tumors correlates with both the
duration of epilepsy and the frequency of seizures [22, 23].
Finally, genetic studies reported a polymorphism in the
promoter region of the IL-1β gene, which is associated with
therapy-resistant temporal lobe epilepsy and in children
with febrile seizures [24]. Ravizza et al. [16] demonstrated
that chronic inﬂammatory reactions are intrinsic to lesional
tissue and sustained by aberrant cells and the recurrence
of seizures in lesional tissue likely contributes to perpetuate
inﬂammation.
Particular attention has been focused on the neuronal
glutamatergic population, consisting of highly diﬀerentiated
cells expressing diﬀerent glutamate receptor subtypes [25].
However,compellingevidenceinhumanepileptogenictissue
and in diﬀerent experimental models of seizures indicates
that anatomical and functional alterations of the GABAergic
networks may also critically contribute to epileptogenesis.
Dysfunction of the inhibitory system may result from loss
of the GABAergic interneurons [26]. Some ﬁndings suggest
that alterations in GABA-mediated synaptic inhibition in
malformations of cortical development could be secondary
to reductions in GABA transporter expression [27, 28]o r
changes in the expression and/or function of speciﬁc GABA
receptor subtypes [29, 30]. Aronica et al. [31] suggest that
the cellular distribution of components of the GABAergic
system in low-grade gangliogliomas, together with the per-
ilesional changes, suggests that alterations of the GABAergic
system may contribute to the complex abnormal func-
tional network of these highly epileptogenic developmental
lesions.
The stem cell epitope CD34 is highly expressed in
gangliogliomas. The presence of a prominent CD34-
immunoreactive cell element in glioneuronal lesions asso-
ciated with focal epilepsies points towards an origin from
dysplastic and/or neoplastically transformed precursor cells
[32]. Several studies [2, 32–34] have noted the ability of
CD34, in highlighting a distinct subset of small cells with
ramifying processes, in seizure-associated focal cortical dys-
plasia, neoplastic lesions like gangliogliomas and pleomor-
phic xanthoastrocytomas, thus aiding in diﬀerentiating them
from other low-grade neoplasms. CD34 is a glycophospho-
protein,normallyexpressedonthesurfaceofhaematopoietic
progenitors of myeloid series, on vascular endothelium, and
on developing central nervous system [35]. Although the
exact nature of these CD34-immunopositive cells is not
known, it has been conjectured that they represent a form
of glioneuronal progenitor cell, as some have been found
to colocalize with traditional neuronal markers [34]. Studies
havesuggestedthatCD34hasaprobableroleincelladhesion
and intracellular signal transduction pathways [36]. Recent
reports [37] have shown that ex vivo bone marrow CD34+
cells express neuronal and oligodendroglial markers or
develop into microglial cells after migrating into the brain.
The fact that these CD34+ cells also express transcription
factors (that are found during early development) elicits the
hypothesisthattheymaybepluripotentembryonic-likestem
cells [37]. A recent study [38] established a role of CD34
as a diagnostic marker in glioneuronal lesions associated
with epilepsy, especially in dual lesions of gangliogliomas
with focal cortical dysplasia, but also indicates a possible
pathogenetic relationship between focal cortical dysplasia
andgangliogliomas,whilesuggestingadiﬀerentaetiologyfor
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Some studies point to a role of genes and pathways in
epilepsy-associated glioneuronal lesions [39, 40], otherwise
associated with rare familial disorders such as tuberous
sclerosis complex (TSC) [41]. TSC is frequently caused
by germline mutations of the TSC1 (hamartin) and TSC2
(tuberin) genes on chromosomes 9q and 16p, respectively.
However, mutations in TSC1 or TSC2 are only found in 85%
of the TSC patients [42]. Hamartin and tuberin constitute
a tumor suppressor complex operating as key factor in
the PI3K/mTOR pathway, which is involved in cell size
control, cell adhesion/migration, and cell fate determination
[39]. Although recent data suggest PI3K pathway activa-
tion in focal cortical dysplasia, gangliogliomas, and TSC-
associated lesions, distinct patterns of activated elements
within the PI3K-signal transduction cascade are observed
between focal cortical dysplasia and cortical tubers in TSC.
Tuberin has been also shown to constitute a chaperon for
hamartin, and its impaired availability may contribute to
aberrant cellular distribution of the complex [43]. Aberrant
expression of PI3K-pathway components (ezrin, radixin,
and moesin) in focal cortical dysplasia and gangliogliomas
was observed [44]. These alterations may relate to com-
promised interactions of dysplastic cellular components in
epilepsy-associated glioneuronal lesions and be involved
in aberrant PI3K-pathway signaling in epilepsy-associated
malformations.
Tyrosine kinase receptors trkA, -B, and -C were observed
to be strongly expressed in neuronal components of gangli-
ogliomas, focal cortical dysplasia and DNET [15]. Fassunke
et al. [45] showed NGFR as the most abundant transcript in
gangliogliomas and suggested gangliogliomas and DNETs to
share some diﬀerential expression patterns, that is, reduced
expression of NELL2, PRKCB1, HSJ2, and ARF3; however,
they identiﬁed several gene expression patterns that were
speciﬁcally altered only in gangliogliomas such as for TRIB1,
ST6GalNac4,andLDB2,relatedtodistinctdysplasticfeatures
of these glioneuronal tumours.
The plasminogen (ﬁbrinolytic) system comprises the
inactive proenzyme, plasminogen, that can be converted
to the active enzyme plasmin by two serine proteases, the
tissue-type plasminogen activator (tPA) and the urokinase-
type plasminog activator (uPA) [46]. In the CNS, increasing
evidence suggests a crucial role of the plasminogen system
in a broad range of physiological and pathological processes
ranging from neuronal development, cell migration, and
invasion, cell growth and apoptosis, immune responses,
inﬂammation, angiogenesis, and regulation of synaptic
remodeling and neuronal plasticity [47, 48]. Several exper-
imental ﬁndings identiﬁed a role for tPA in the mechanisms
underlying seizure activity [48, 49]. Interestingly, induction
of plasminogen activators (PAs) has been observed in
diﬀerent experimental models of epilepsy [50], and gene
expression proﬁle analysis of gangliogliomas revealed that
both tPA and uPA represent one of the most upregulated
genes in these epileptogenic lesions. Recently, the cellular
distribution of uPA and uPAR has been characterized in rat
hippocampus during epileptogenesis [50]. Iyer et al. [51]
demonstrated that activation of the plasminogen system,
as exempliﬁed by increased expression of tPA and uPA,
indeed occurs in human focal chronic refractory epilepsy,
conﬁrming the studies performed in experimental models
of temporal lobe epilepsy. The chronic expression of PAs
together with the upregulation of uPAR might contribute
to the mechanisms underlying the epileptogenicity of focal
lesions, through direct modulation of neuronal activity or,
indirectly, through regulation of the inﬂammatory response
and/or epileptogenic tissue remodeling. Several mechanisms
are possibly involved, including a direct regulation of
neuronal excitability via NMDA receptors [48]. Additionally,
bothtPAanduPAmaycontributetothedisruptionofblood-
brain barrier integrity and ampliﬁcation of inﬂammatory
inﬁltrates [52], which have been recently shown to play a
critical role in chronic refractory epilepsy [17, 53]. Finally we
have to consider the key role of the PA system in the com-
plex tissue remodeling that occurs during epileptogenesis,
such as axonal reorganization, angiogenesis, and astrogliosis
[54].
The resistance to the pharmacological treatment with a
broad range of antiepileptic drugs (AEDs) is characteristic
of these developmental lesions [1, 55]. The mechanisms
underlying this multidrug resistance are still elusive. One
possiblemechanismtoaccountforthismedicalintractability
is the inadequate drug concentration in the epileptogenic
areas. In the last years attention has been focused on mul-
tidrug transporters, such as P-glycoprotein (P-gp) and the
family of multidrug resistance-associated proteins. Several
reports indicate that common AEDs, such as carbamazepine,
phenytoin, and valproate, are substrate of these multidrug
transporters[56,57].Thus,changesintheexpressionofboth
P-gp and multidrug resistance-associated proteins (MRPs)
may critically regulate the extracellular brain concentration
of a broad range of AEDs, contributing to the pharmaco-
resistance. The overexpression of multidrug transporter pro-
tein is a common feature of both focal cortical dysplasia and
gangliogliomas[55].Thisoverexpressionislikelyresponsible
for, or at least contributes to, the intrinsic drug resistance of
these developmental lesions. The cell-speciﬁc expression of
MRP1 and P-gp would impair drug responsiveness at three
consecutive steps: (1) at the level of the endothelial cells in
lesional capillaries (P-gp), leading to a decreased tissue drug
concentrations; (2) at the level of the astrocytic end-foot
processes surrounding brain capillaries and neurons (P-gp
and MRP1), promoting a ﬂux from brain extracellular space
back to the bloodstream, thus reducing the drug available
for interaction with its targets in neurons; (3) at the level
of the neuronal and neuroglial epileptogenic component of
the lesion, interfering with the intracellular activities of the
AEDs.SeveralinhibitorsofP-gpand,morerecently,ofMRPs
are available and are currently in the clinical trial stage in
human cancer patients [58]. Thus, evaluation of the possible
use of these inhibitors as adjunctive treatment in pharmaco-
resistant epilepsy is certainly worthwhile.
3. Treatment
Epilepsy that is often resistant to pharmacological treatment
is a common presenting symptom of glioneuronal tumors
(in 75% of cases), and the temporal lobe is the most4 ISRN Neurology
frequent location (in 60% of cases). The best approach
to management of epilepsies related to benign tumours
is controversial. Several studies have suggested a very
benign clinical course in most patients with gangliogliomas.
However, tumor recurrence, malignant progression, and
secondary glioblastoma multiforme are observed in some
patients [2, 5, 59]. Malignant transformation has been
associated with incomplete tumor resections and radiation
therapy [5, 60].
Epilepsy control represents the main therapeutic goal [1,
2, 5]. Findings from several studies have indicated that early
surgery for children with the forms of epilepsy associated
with primary brain tumors can improve the patient’s psy-
chosocial and intellectual development, reduce the incidence
of secondary epileptogenesis, ensure an accurate diagnosis,
and prevent the malignant transformation of otherwise
benign tumors [1, 2, 61, 62].
Controversy exists regarding the most appropriate surgi-
cal treatment for children suﬀering from epilepsy associated
with brain tumors. Some investigators consider complete
tumor excision suﬃcient [62–64] whereas others advocate
the identiﬁcation and resection of epileptogenic zones as
necessary to provide a good seizure outcome [1, 5, 59, 65].
Few studies, however, have speciﬁcally focused on the
long-term seizure outcome after lesionectomy in selected
series of children harboring glioneuronal tumors. Other
authorshaveinvestigatedseizureoutcomeafterlesionectomy
in groups in which glioneuronal tumors occurred together
with other diﬀerent epileptogenic types of tumor [62, 63].
Giulioni et al. [66] demonstrated that lesionectomy
results in good seizure control in the majority of children
with epileptogenic glioneuronal tumors.
Recently Yang et al. [67] reviewed the modern literature
regarding the eﬀects of early surgical intervention on the
clinical outcome of patients with ganglioglioma: seizure con-
trol was signiﬁcantly improved when surgical intervention
occurred less than 3 years after symptom onset (78% versus
48%), thus an early surgical intervention is signiﬁcantly
associated with improved clinical seizure control.
Furthermore, glioneuronal tumors presenting with
epilepsy were observed to have relatively benign biological
behavior. The seizure outcomes do not appear to be related
to the duration of epilepsy, seizure type, and frequency or
completeness of tumor removal. The completeness of the
tumor resection is of paramount importance in avoiding
tumor progression and malignant transformation, which are
rare in cases of epileptogenic glioneuronal tumors [66].
Finally, despite the probable developmental defects in
glioneuronal proliferation in the relevant malformations of
cortical development, classes of drugs are already avail-
able that can inhibit cell proliferation. In particular, the
recent discovery of mTOR pathway dysregulation in TSC,
as well as focal cortical dysplasia and gangliogliomas,
oﬀers a remarkably direct “bench-to-bedside” strategy
for treating these malformations of cortical development.
Rapamycin will speciﬁcally inhibit the mTOR pathway,
leading to decreased cellular proliferation [42], and has
already been tested in clinical trials for tumor growth in TSC
[68].
4. Conclusion
Patients with drug-resistant epilepsy associated to glioneu-
ronal tumors should undergo evaluation in dedicated
epilepsy surgery programmes. The procedure should include
diagnosis of the type of tumour by advanced imaging and
radio-nuclear methods followed by rapid determination
of intractability to antiepileptic drug treatment. Although
manypatientsbecomeseizure-freewithastandard“lesionec-
tomy,” a signiﬁcant proportion of patients continue to have
seizures despite lesionectomy and might beneﬁt from a more
extensive surgical resection involving broader perilesional
regions. A large-scale screening of currently available drugs
have identiﬁed a number of drugs that can upregulate
astrocyte glutamate transporters, which may counteract the
detrimentaleﬀectsofimpairedastrocyteglutamatetransport
seen in epilepsy and other neurological disorders [11].
Glial-selective drugs may also have the beneﬁt of fewer
neurologicalandcognitivesideeﬀectsthanonewouldexpect
with a comparable drug aﬀecting neurons.
Future advances in imaging techniques and molecular
markers might be able to more accurately identify the true
extent of the epileptogenic zone that needs to be resected to
achieve seizure freedom. Further advances into the distinct
pathophysiologiesofepilepsyassociatedwithdiﬀerenttumor
histologies will promote an even more rational choice of
medical therapy.
An evolving understanding of the various mechanisms
of tumor-related epileptogenicity and the role of the per-
ilesional tissue may also lead to a more deﬁned surgical
objective for the patient presenting with tumor-related
epilepsy. In addition to pharmacological interventions,
future therapeutic gene replacement or gene manipulation
approachesmayeventuallyallowamoredeﬁnitivecorrection
of the molecular genetic defects in these diseases.
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